CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Tocilizumab

Tocilizumab

Last Updated: July 29, 2013

Result type: Reports

Project Number: SR0343-000

Product Line: Reimbursement Review

Generic Name: Tocilizumab

Brand Name: Actemra

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Arthritis, polyarticular juvenile idiopathic

Indications: Polyarticular juvenile idiopathic arthritis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 19, 2014

Recommendation Type: List with criteria/condition

Tocilizumab

Files